Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
porustobart + tislelizumab
- Development stage
- Unknown
- Lead developer
- Harbour BioMed
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Porustobart + tislelizumab is a combination of two monoclonal antibodies used in oncology immunotherapy. **Porustobart** (HBM4003) is a fully human heavy chain only monoclonal antibody targeting CTLA-4, developed using Harbour Mice technology by Harbour BioMed. **Tislelizumab** (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody from BeiGene, designed to minimize Fcγ receptor binding on macrophages to reduce antibody-dependent phagocytosis, a known resistance mechanism to anti–PD-1 therapy. The combination aims to synergistically enhance immune-mediated tumor cell killing by jointly inhibiting negative immune checkpoints CTLA-4 and PD-1, respectively. It's being investigated in phase I/II studies for advanced solid tumors, such as melanoma and metastatic colorectal cancer. Early data suggest promising anti-tumor activity and a manageable safety profile in immunotherapy-naive patients, including those with difficult-to-treat subtypes like mucosal melanoma[1][5].
- Other names
- porustobart + tislelizumab
02
Targets
CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on porustobart + tislelizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on porustobart + tislelizumab.